Qiming Venture Partners Portfolio Companies Dominate China AI Top 300 List

Recently, Ifenxi released its inaugural China AI Tech 300 ranking. The list evaluates companies on their technical capabilities and commercialization potential, offering a comprehensive scan of China's systematic breakthroughs in AI technology.

Qiming Venture Partners portfolio companies including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Dingdong Maicai (NYSE:DDL), Zhihu (NYSE:ZH, 02390.HK), Meitu (01357.HK), Hesai Technology (NASDAQ:HSAI), UBTECH (09880.HK), Unisound, Transwarp Technology (688031.SH), WeRide (NASDAQ:WRD), Zhipu AI, and Biren Technology were named to the list.

Xiaomi, Meituan, Bilibili

Dingdong Maicai, Zhihu, Meitu, Hesai Technology

UBTECH, Unisound, Transwarp Technology

WeRide, Zhipu AI, Biren Technology, and others

Named to

China AI Tech 300 Ranking

Selection Criteria

- China AI Tech 300 Ranking

Ifenxi ranked companies based on disclosed revenue from the most recent 12-month period (as of March 28, 2025). Eligible companies possess AI capabilities, including robust AI R&D teams, AI patents, and software copyrights; either package their AI capabilities as products or services for external delivery, or have AI capabilities that are essential to their products, services, or business processes.

Source | Ifenxi

Past Coverage

Qiming Stars | Eight Qiming Venture Partners Portfolio Companies Named to Synced AI China 2024 Annual Ranking

Qiming Perspectives | Qiming Venture Partners Duane Kuang: AI Investment in China Is Not Overheated — It Should Attract Capital From Around the World

Qiming Perspectives | Qiming Venture Partners Alex Zhou: A "Super AI App" Will Likely Emerge This Year

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 exiting through listings on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.